|Predecessor||Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)|
|Founded||March 2005California, U.S.in|
|Headquarters||Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland|
|Bruce C. Cozadd|
(Chairman & CEO)
|Revenue||US$1.618 billion (2017)|
|US$528.8 million (2017)|
|US$487.8 million (2017)|
|Total assets||US$5.123 billion (2017)|
|Total equity||US$2.713 billion (2017)|
Number of employees
|~1,210 (February 2018)|
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA).
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
On February 18, 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.
On April 26, 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company successfully sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|url=(help). 34 (2). January 15, 2014. p. 10.